comprehensive -WSS

comprehensive

author：hotspot 2025-09-27 23:32:00 - browse：5

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： The lessons of Aduhelm, an Alzheimer's drug that was not to be

explore

WSS

Cognito secures funding to test medical device for Alzheimer's

The Harvard botanist who searched for psychedelics in the Amazon

Novo Nordisk to expand supply of Wegovy for U.S. patients

Cybersecurity threat forces Lurie Children's to take systems offline

NIH study of ME/CFS points to clear biological hallmarks

R1 RCM gets $5.8 billion buyout offer from private equity firm

Wikipedia

comprehensive

explore

Guidelines to prevent youth baseball injuries need more muscle

Do digital therapeutics have a future in medicine?

Medical records are filled with copy

General Catalyst, Summa Health deal will turn on physician buy

Peter Hotez and the public health issue of online harassment

Vertex non

Medicare proposal to cover medical devices draws a mixed reaction

Quicker fix for pulse oximeters urged during FDA public meeting

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Biden administration opens offers in Medicare drug price negotiations

focus

Commercial surrogacy can be ethical, despite pope’s claims

The Harvard botanist who searched for psychedelics in the Amazon

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Do digital therapeutics have a future in medicine?

He's a Nobel laureate. Critics say he was misleading on Covid

Woodcock on FDA’s accelerated approval and her next chapter

focus

hotspot

explore

leisure time